Estudio SHIFT: (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Un CAMBIO en el tratamiento de la insuficiencia cardíaca

despite the progress made in the treatment of heart failure, it remains associated with high morbidity and mortality. several studies link elevated heart rate to cardiac remodeling and increased morbidity and mortality with a higher incidence of cardiovascular events. but is the heart rate an independent risk factor in patients with heart failure? does the reduction in heart rate in patients with heart failure may provide additional benefit added to the recommended therapeutic with beta receptor blockers? the study shift (systolic heart failure treatment with the if inhibitor ivabradine trial) allowed us to evaluate the effects of ivabradine versus placebo in patients with heart failure due to left ventricular dysfunction with a baseline heart rate> 70 beats/minute in functional class ii to iv of the new york heart association. this study showed that the addition of ivabradine in patients with low ejection fraction, heart rate a？￥ 70 beats per minute and sinus rhythm is associated with a significant reduction in mortality. shift study contributed to a shift in the way we see the heart failure to show us that we have more than the intervention on the renin-angiotensin-aldosterone and the adrenergic system that is highly beneficial for our patients and our health system.